NCT07648602Recruiting
PPD™ CorEvitas™ Psoriasis (PSO) Early Treatment Response Non-Interventional Study
Source: ClinicalTrials.gov · Last updated 26 Aug 2026
Brief summary (registry, in English)
This is a 24-week prospective, single-arm cohort, study of patients initiating advanced therapy for the treatment of moderate-to-severe plaque PSO. Eligible patients must be willing to be seen in-person by their treating physician for a Baseline visit (with first dose of the advanced therapy occurring within 14 days), and at 16 (+/- 5 days) and 24 weeks (+14 days) calculated based on date of first dose of the advanced therapy and must provide informed consent prior to enrolling in the study or completing study-specific questionnaires or procedures. Data will be collected from both subjects and their treating dermatology provider at predetermined scheduled intervals (Baseline, Week 16 and Week 24) using a structured and standardized data collection tool.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 2500 (estimated)
- First submitted
- 5 Jun 2026
- Start date
- 1 Jun 2026
- Primary completion date
- 31 Dec 2036
- Lead sponsor
- CorEvitas
- Diseases
- Psoriasis
- NCT number
- NCT07648602
What you commit to
- Study type: Observational
- Planned participants: 2500
- From 1 Jun 2026 to the primary completion date, 31 Dec 2036
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients that do not receive at least 1 dose of the advanced therapy within 14 days following the Enrollment/Baseline visit for the study.
Other
- An individual who meets any of the following criteria will be excluded from participation in the study:
- Patient is participating in a blinded clinical trial.
- Patients cannot be concurrently enrolled in both the CorEvitas PSO Registry and the PPDTM CorEvitasTM Psoriasis (PSO) Early Treatment Response Non-Interventional Study. A. Patients currently enrolled in the CorEvitas PSO Registry are ineligible for participation in the PPDTM CorEvitasTM Psoriasis (PSO) Early Treatment Response Non-Interventional Study.
- Patients otherwise meeting eligibility criteria can be enrolled in the PPDTM CorEvitasTM Psoriasis (PSO) Early Treatment Response Non-Interventional Study C. Following completion or at time of Exit from the PPDTM CorEvitasTM Psoriasis (PSO) Early Treatment Response Non-Interventional Study, patients will be eligible to enroll into the CorEvitas PSO Registry for long term follow-up at the standard of care cadence supported by the registry. A separate Informed consent will be obtained.
Who the study is looking for
- To be eligible to participate in this study, an individual must meet all the following criteria:
- Patient is at least 18 years of age at the time of study enrollment.
- Patient has a diagnosis of moderate to severe plaque psoriasis based on an investigator Global Assessment (IGA, score of 3 or 4 at the time of Enrollment).
- Patient is initiating new Eligible Medication for the first time for the treatment of PSO.
- Patient is willing and able to provide informed consent to participate in this study.
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CorEvitas, LLC Coordinator of this site? Confirm its status | Waltham | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.